BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders - 2Doctors thought he had cancer. An offhand suggestion led to a rare diagnosis.
- 3The Manual for Electric Vehicles that will be hot dealers in 2023
- 4Beating Wellbeing Difficulties: Individual Victories in Health
- 5EU-funded BioSupPack project turns brewery waste into bioplastics
- From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season
- The Best 10 Innovation Developments of the Year
- Trump declares Christmas Eve and Dec. 26 federal holidays: What does that mean?
- Witness the elegance of the cosmic butterfly in a remarkable telescope photo
- Instructions to Improve Your Mental Exploration with Cutting edge Measurements
- Underestimated Metropolitan Experience Urban communities On the planet
- Viable Monetary Tips to Advance Your Monetary Circumstance
- Best Exciting ride: Which One Rushes You the Most?
- 6 Well known Nissan Vehicles in the U.S.
